Physician profile
Arun A Pol
NPI 1205015534
$95,302.54
in general payments reported to CMS, 2019-2025
32 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,206 · 2020: $460 · 2021: $17K · 2022: $11K · 2023: $26K · 2024: $21K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Honoraria: $16K · Food and Beverage: $7,792 · Travel and Lodging: $3,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,250.00 |
| Honoraria | $16,150.00 |
| Food and Beverage | $7,792.15 |
| Travel and Lodging | $3,778.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $84,757.69 | 2019-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,521.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,425.66 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $743.12 | 2019-2024 | Lybalvi |
| Tris Pharma INC | $696.14 | 2020-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $694.84 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $669.10 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $645.01 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $513.37 | 2019-2024 | Jornay Pm |
| Corium, LLC | $468.52 | 2021-2025 | Azstarys |
| Neos Therapeutics, LP | $454.10 | 2019-2025 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $407.30 | 2024-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $355.63 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $311.00 | 2022-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $308.37 | 2020-2025 | Fanapt, Hetlioz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $189.14 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $173.71 | 2019-2023 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $141.89 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $115.57 | 2024-2025 | Relexxii |
| Noven Pharmaceuticals, INC. | $114.23 | 2024 | Xelstrym |
| Neurocrine Biosciences, INC. | $110.51 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $105.28 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $75.11 | 2023-2024 | Xelstrym, Secuado |
| Shire North American Group INC | $59.25 | 2019 | |
| Allergan, INC. | $48.21 | 2020 | |
| Adlon Therapeutics L.P. | $47.97 | 2019-2021 | |
| Avion Pharmaceuticals | $46.55 | 2023-2024 | Methylphenidate Hydrochloride, Relexxii |
| Owp Pharmaceuticals, INC. | $39.26 | 2019 | |
| Tempus Ai, INC | $20.92 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.10 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $13.86 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Pol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.